Although combination and augmentation treatments are useful in patients with resistant depression (5, 6) , over one-third do not benefit from multiple combination. The addition of electroconvulsive therapy (ECT), still considered to be the treatment of choice for severe depression, alone or with other pharmacologic agents, leaves 40% of patients with marked depressive symptomatology (7, 8) .
Transcranial magnetic stimulation (TMS) has been shown to improve depressive symptoms both in uncontrolled (9,10) and in sham-controlled studies (11, 12) . Pridmore substituted rapid TMS treatments for right unilateral (RUL) ECTs, showing that the TMS-substituted group did as well as the group that continued to receive ECT (13) .
We describe below the first successful use of combined RUL ECT and bilateral TMS.
Case Report
The patient is a woman, aged 39 years, referred to the mood disorders service for treatment resistance. Under our care, she received adequate trials with serzone; clomipramine augmented by cytomel, lithium, and risperidone; phenelzine; parnate up to 100 mg daily augmented by quetiapine; mirtazapine with topiramate and lithium; fluoxetine and tryptophan; nortriptyline; and citalopram augmented by lamotrigine. A full course of bifrontal ECT was associated with severe cognitive disturbances and only partial response.
Our patient, who had shown a partial response when participating in a bilateral TMS study, was offered an open trial of RUL ECT and bilateral TMS.
At the start of treatments, her Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI) scores were 35 and 55, respectively. On Mondays, Wednesdays, and Fridays, she received 10 ECTs (RUL placement, pulse width 1.0 ms, 60 to 90 Hz, 3 to 4 seconds, and 800 mamp with Mecta [Tualatin, Oregon: Customs Systems Associates]). On Tuesdays and Thursdays, she received high-frequency TMS (that is, 20 trains of 12 Hz stimulation with a train of 8 seconds at 110% of motor threshold) over the left prefrontal cortex and low frequency (that is, 2 trains of 1 Hz stimulation with a train duration of 60 seconds and an intertrain interval of 3 minutes) over the right cortex. At the end of our course, her depression remitted, with HDRS and BDI scores dropping to 4 and 11, respectively. She was discharged home. Her Mini-Mental Status Exam Score was 28 out of 30.
Discussion
Despite the advances in treatment of depression, 10% to 30% of all depression patients remain refractory to treatment. Although ECT is still considered the treatment of choice for severe depression, there is no consensus or guideline suggesting the next steps for patients who do not tolerate or do not respond to a course of ECT. We are therefore describing a treatment-refractory patient with depression who obtained full remission for the first time with a combined treatment of ECT and TMS. The combined treatments were well tolerated.
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Re: Treatment Noncompliance With Orally Disintegrating Olanzapine Tablets
Dear Editor: Dr Freudenreich reported on the case of a woman, aged 52 years, with chronic schizophrenia and covert noncompliance with the orally disintegrating formulation of olanzapine (1). The patient was able to "cheek" the medication wafer behind her front teeth near the gum line. Consequently, no clinical improvement was observed. Once this was discovered, the patient was placed on haloperidol decanoate. Dr Freudenreich concluded that fast-dissolving medication is no substitute for parenteral medication.
Although adherence to medication is an important concern, parenteral medication is not always the answer. Treatment compliance to haloperidol decanoate is not guaranteed if the patient fails to attend clinic appointments. Moreover, haloperidol is inferior in terms of effects on negative symptoms, cognition, and mood, compared with atypical antipsychotics (2) . It is possible that, by persisting with a treatment course of an atypical antipsychotic, improvements in overall well-being, including cognition and mood, may lead to improved insight and a better functional outcome.
We have also observed the "cheeking" of olanzapine wafers in a small minority of
